RPL7C Antibody

What is RPL7 and why is it significant in research?

RPL7 is a component of the 60S ribosomal subunit with unique structural and functional properties beyond its role in protein synthesis. It contains an N-terminal basic region-leucine zipper (BZIP)-like domain and the RNP consensus submotif RNP2, which mediates homodimerization and stable binding to DNA and RNA in vitro, with preference for 28S rRNA and mRNA. The protein can inhibit cell-free translation of mRNAs, suggesting a regulatory role in the translation apparatus . Additionally, RPL7 has been identified as an autoantigen in patients with systemic autoimmune diseases such as systemic lupus erythematosus, making it relevant for immunological research .

What are the validated applications for anti-RPL7 antibodies?

Anti-RPL7 antibodies have been validated for several research applications with varying degrees of optimization. Western blotting represents the most extensively validated application, with recommended dilutions typically around 1/1000 . These antibodies detect a band of approximately 29 kDa in various cell lysates, including Raji cells . Some commercial anti-RPL7 antibodies have also been validated for ELISA applications . The antibodies show cross-reactivity with human, mouse, and rat samples , making them versatile tools for comparative studies across species. Validation typically involves testing against whole cell lysates to ensure specificity and performance in complex biological samples.

How should I optimize Western blotting protocols for RPL7 detection?

Optimizing Western blotting for RPL7 detection requires careful consideration of several parameters to ensure specific and reproducible results. The following table outlines key optimization parameters:

For tissues or cell types not previously tested, preliminary experiments with gradient dilutions of both sample and antibody are recommended to establish optimal conditions.

What approaches can I use to validate antibody specificity for RPL7?

Validating the specificity of anti-RPL7 antibodies is crucial for ensuring reliable experimental results. A multi-faceted approach to validation should include:

• Positive and negative controls: Use cell lines with known RPL7 expression as positive controls. For negative controls, consider RNA interference approaches to reduce RPL7 expression or use pre-immune serum.

• Peptide competition assays: Pre-incubation of the antibody with the immunizing peptide (between amino acids 6-35 from the N-terminal region of human RPL7 ) should significantly reduce or eliminate specific signal.

• Cross-validation with multiple antibodies: Use antibodies targeting different epitopes of RPL7 to confirm specificity of detection.

• Orthogonal techniques: Correlate protein detection with mRNA levels using RT-qPCR or with mass spectrometry data when possible.

• Analysis in multiple sample types: Test antibody performance across different cell types, tissues, and species to understand potential limitations.

The following validation workflow is recommended before undertaking critical experiments:

How can I study RPL7's role in translation regulation using specific antibodies?

Investigating RPL7's role in translation regulation requires integrating antibody-based detection with functional assays. Several advanced approaches can provide insights into RPL7's regulatory functions:

• Polysome profiling: After cellular fractionation on sucrose gradients, anti-RPL7 antibodies can be used for immunoblotting of individual fractions to analyze RPL7 distribution across monosomes, polysomes, and ribosomal subunits.

• RNA immunoprecipitation (RIP): Given RPL7's ability to bind 28S rRNA and mRNA , anti-RPL7 antibodies can precipitate RPL7-RNA complexes, followed by RNA extraction and analysis to identify associated transcripts.

• Proximity-dependent biotinylation (BioID or TurboID): Fusion of biotin ligases to RPL7 followed by streptavidin pulldown and detection with anti-RPL7 antibodies can reveal proximal interactors in the translation machinery.

• In vitro translation assays: Depletion of RPL7 using antibodies can help evaluate its specific contribution to translation efficiency and fidelity.

Protocol example for RNA immunoprecipitation using anti-RPL7 antibodies:

What methods can detect post-translational modifications of RPL7 using antibodies?

Post-translational modifications (PTMs) of RPL7 may regulate its function in translation and other cellular processes. The following approaches can be employed to study RPL7 PTMs:

• 2D gel electrophoresis: Combining isoelectric focusing with SDS-PAGE followed by immunoblotting with anti-RPL7 antibodies can resolve differently modified forms of the protein.

• Phospho-specific antibodies: While not commonly available commercially, custom phospho-specific antibodies against predicted RPL7 phosphorylation sites can be developed.

• Immunoprecipitation followed by mass spectrometry: Anti-RPL7 antibodies can be used to purify the protein, followed by mass spectrometry analysis to identify and quantify PTMs.

• Phos-tag SDS-PAGE: This technique specifically retards the migration of phosphorylated proteins, allowing separation of phosphorylated from non-phosphorylated RPL7 before immunoblotting.

Experimental workflow for detecting RPL7 PTMs:

How can I interpret inconsistent RPL7 detection across different cell types?

Inconsistent detection of RPL7 across different cell types may result from multiple biological and technical factors. Consider the following when interpreting variable results:

• Expression level variation: As a ribosomal protein, RPL7 expression correlates with protein synthesis rates, which vary among cell types. Highly proliferative cells typically express higher levels of ribosomal proteins.

• Post-translational modifications: Differential modification patterns may affect antibody recognition, particularly if the epitope region is modified.

• Sample preparation effects: Different cell types may require adjusted lysis conditions to efficiently extract RPL7, especially if it is tightly associated with the nucleolus or ribosomes.

• Splice variants or isoforms: Although not extensively documented for RPL7, potential isoforms might be expressed differentially across tissues.

Systematic approach to addressing inconsistent detection:

What strategies should I employ when anti-RPL7 antibodies show non-specific binding?

Non-specific binding is a common challenge when working with antibodies. For anti-RPL7 antibodies, try these optimization strategies:

• Antibody dilution optimization: Increasing the dilution may reduce non-specific binding while maintaining specific signal. Test a range of dilutions (e.g., 1:500 to 1:5000) to determine optimal conditions.

• Blocking optimization: Test different blocking agents (BSA, non-fat milk, normal serum) and concentrations (3-5%) to reduce background.

• Wash protocol adjustment: Increase the number, duration, or stringency of washes. Adding higher concentrations of detergent (e.g., 0.1-0.3% Tween-20) to wash buffers can help reduce non-specific interactions.

• Sample preparation refinement: More stringent lysis and clarification steps can reduce interfering components in complex samples.

• Pre-adsorption of antibody: Incubating the antibody with acetone powder of tissues/cells lacking the target can reduce cross-reactivity.

Troubleshooting guide for non-specific binding:

How can anti-RPL7 antibodies contribute to studying ribosome heterogeneity?

Ribosome heterogeneity is an emerging area of research, and anti-RPL7 antibodies can provide valuable insights into specialized ribosomes and their functions:

• Differential ribosome immunoprecipitation: Anti-RPL7 antibodies can be used to immunoprecipitate ribosomes from different cellular compartments or under various stress conditions to analyze potential compositional differences.

• Proximity labeling in specific cellular regions: Combining anti-RPL7 antibodies with proximity labeling techniques can reveal compartment-specific ribosome compositions.

• Single-cell analysis: Immunofluorescence with anti-RPL7 antibodies can help visualize cell-to-cell variation in ribosome distribution and abundance.

• Tissue-specific ribosome characterization: Comparing RPL7 incorporation into ribosomes across different tissues may reveal specialized ribosome populations.

• Ribosome assembly analysis: Time-course studies with anti-RPL7 antibodies can track the incorporation of RPL7 into maturing ribosomes.

The following experimental approach could be employed to study ribosome heterogeneity:

What approaches can integrate anti-RPL7 antibodies with emerging single-cell technologies?

Integrating anti-RPL7 antibodies with single-cell technologies offers exciting opportunities to understand ribosome dynamics at unprecedented resolution:

• Single-cell Western blotting: Newly developed techniques allow protein analysis at the single-cell level, potentially revealing cell-to-cell variability in RPL7 expression or modification.

• Mass cytometry (CyTOF): Metal-conjugated anti-RPL7 antibodies can be used in mass cytometry panels to analyze ribosomal protein expression alongside dozens of other cellular markers.

• Spatial transcriptomics with protein detection: Combining in situ RNA sequencing with immunofluorescence using anti-RPL7 antibodies can correlate ribosome localization with actively translating mRNAs.

• Single-molecule imaging: Fluorescently labeled anti-RPL7 antibody fragments or nanobodies can be used for super-resolution imaging of individual ribosomes.

• Microfluidic approaches: Antibody-based capture of individual cells based on RPL7 expression levels can enable downstream single-cell analysis.

Implementation strategies for single-cell analysis:

How can anti-RPL7 antibodies be utilized in studying autoimmune conditions?

RPL7 has been identified as an autoantigen in systemic autoimmune diseases such as systemic lupus erythematosus (SLE) . Anti-RPL7 antibodies can be valuable tools in studying these conditions:

• Autoantibody detection assays: Commercial anti-RPL7 antibodies can serve as positive controls in assays designed to detect anti-RPL7 autoantibodies in patient sera.

• Epitope mapping: Different anti-RPL7 antibodies recognizing distinct epitopes can help identify immunodominant regions that are frequently targeted by autoantibodies.

• Immune complex characterization: Anti-RPL7 antibodies can help identify and isolate immune complexes containing RPL7 from patient samples.

• Mechanistic studies: These antibodies can investigate how RPL7 might become exposed to the immune system during cell death or stress.

Protocol for detecting anti-RPL7 autoantibodies in patient samples:

What is the potential of anti-RPL7 antibodies in cancer research?

Emerging evidence suggests altered ribosomal protein expression in various cancers. Anti-RPL7 antibodies can contribute to cancer research in several ways:

• Expression profiling: Immunohistochemistry using anti-RPL7 antibodies can assess expression patterns across tumor types and correlate with clinical outcomes.

• Biomarker development: Changes in RPL7 localization or modification might serve as diagnostic or prognostic markers in certain cancers.

• Specialized ribosome investigation: Anti-RPL7 antibodies can help characterize potential "oncosomes" - specialized ribosomes that preferentially translate oncogenic mRNAs.

• Therapy response monitoring: Changes in RPL7 expression or incorporation into ribosomes might correlate with response to therapies targeting protein synthesis.

• Drug development: Similar to approaches being developed for other cancer targets, tiny antibody fragments like nanobodies could potentially be engineered against specific RPL7 epitopes for therapeutic applications .

Research applications in cancer studies:

How might new antibody technologies enhance RPL7 research?

Emerging antibody technologies offer exciting possibilities for advancing RPL7 research:

• Recombinant antibody formats: Single-chain variable fragments (scFvs) or nanobodies derived from existing anti-RPL7 antibodies could provide improved access to sterically restricted epitopes within ribosome complexes.

• Intrabodies: Cell-permeable antibody formats that can target RPL7 in living cells could enable dynamic studies of ribosome assembly and function.

• Antibody-enzyme fusions: Anti-RPL7 antibodies fused to enzymes like peroxidases or luciferases could enable highly sensitive detection without secondary reagents.

• Bispecific antibodies: Constructs recognizing both RPL7 and other ribosomal components could help isolate specific ribosome subpopulations.

• Photocrosslinking antibodies: Anti-RPL7 antibodies with photoactivatable groups could covalently capture transient interaction partners upon light stimulation.

These emerging technologies could significantly expand the research toolkit beyond conventional polyclonal antibodies currently available .

What computational approaches can enhance antibody-based RPL7 research?

Computational methods can significantly augment experimental approaches using anti-RPL7 antibodies:

• Epitope prediction: Computational algorithms can predict RPL7 epitopes likely to be accessible in various cellular contexts, guiding antibody selection.

• Structural modeling: Incorporating antibody binding data into ribosome structural models can provide insights into RPL7's positioning and interactions.

• Machine learning for image analysis: Advanced algorithms can extract quantitative data from immunofluorescence images, detecting subtle changes in RPL7 localization or abundance.

• Network analysis: Integrating antibody-based protein interaction data with transcriptomic datasets can reveal functional networks involving RPL7.

• Virtual screening: In silico approaches can identify compounds that might disrupt specific RPL7 interactions identified through antibody-based methods.

Implementation strategies for computational enhancement:

By implementing these advanced computational approaches alongside cutting-edge antibody technologies, researchers can gain unprecedented insights into RPL7's roles in normal physiology and disease states.